A Prospective European Trial Comparing Laparotomy, Laparoscopy, Robotic-Assisted, and Transanal Total Mesorectal Excision Procedures in High-Risk Patients with Rectal Cancer: The RESET Trial
Philippe Rouanet,Mario Guerrieri,Pablo Lemercier,Emre Balik,Eddy Cotte,Antonino Spinelli,Marcos Gómez-Ruiz,Albert Wolthuis,Emilio Bertani,Anne Dubois,on behalf the RESET study group,Emre Özoran,Michele Carvello,Jesús Pedro Paredes-Cotoré,Francesca Di Candido,Laura Lorenzon,Alejandro Solis,Andrea Coratti,Daniela Rega,Carmen Cagigas Fernández,Matteo Palmeri,Jim Khan,María Fernández-Hevia,Andre D'Hoore,Roberto Coppola,Quentin Denost,Ignacio Aguirre-Allende,Nerea Borda-Arrizabalaga,Guillaume Piessen,Leonardo Vincenti,Ibrahim Halil Özata,Paolo Pietro Bianchi,Alain Valverde,Eric Rullier,Matti Kairaluoma,Antonio Navarro-Sánchez,Gill Talvinder,Jaime Zorrilla Ortúzar,Benoit Romain,John A Conti,Jorge Luis Otero-Díez,Cécile de Chaisemartin,Adeline Germain,Mehrdad Jafari,Valeria Andriola,Frederic Dumont,Daniel Trigero-Cánovas,Juan Ocaña Jiménez,Thalia Petropoulou,Vicente Simó Fernández,Cécile Brigand,Fernando Mendoza-Moreno,Carlos Jezieniecki Fernández,Beatriz Martín-Pérez,Damiano Caputo,Pirita Varpe,Daniel Perez,Gianluca Pellino,Thierry Bensignor,Zaher Lakkis,Filippos Sagias,Bertrand Celerier,Clément Dubois,Richard Douard,Veronika Zver,Bernard Lelong,Sandra Lario Perez,Nader K Francis,Jean-Luc Faucheron,Antoine Brouquet,Federico Perna,Tero T Rautio,Heikki Takala,Ester Kreisler Moreno,Anna Lepisto,Simona Borin,Lucia Salvischiani,Luca Morelli,Serge Rohr,Maria José Alcaide,Alex Kartheuser,Aaron Quyn,Kamal Aryal,Orestis Ioannidis,Roel Hompes,Rogier Crolla
DOI: https://doi.org/10.1097/SLA.0000000000006534
2024-09-12
Abstract:Objective: To compare total mesorectal excision (TME) techniques combined with sphincter-sparing procedure in high-risk patients (HRPs). Background: TME is the standard treatment for rectal cancer, but can be challenging in HRPs. The available surgical approaches must be compared, especially in HRPs. Methods: Prospective, observational, multicenter trial to compare laparotomy (OTME), laparoscopy (LTME), robotic-assisted surgery (RTME), and transanal surgery (TaTME) in HRPs. The composite primary outcome included circumferential radial margin (CRM) ≥1mm, TME grade II-III, and absence of Clavien-Dindo grade III-IV complications. Three propensity score analyses were performed (LTME vs. RTME, RTME vs. TaTME, LTME vs. TaTME). Results: 1078 HRPs (75% of men, median body mass index of 27 kg/m2, 50% of tumors in the lower third of the rectum) underwent surgery. The RTME and TaTME groups included patients with more advanced and lower tumors and coloanal anastomosis (P<0.001). Operative time was longer for RTME surgery (P<0.001). Conversion rate was similar for minimally invasive procedures (4.5%). The global R0 resection rate was 96% without difference among techniques. The primary outcome rates were 82.4%, 64.3%, 74.7%, and 80.3% for LTME, OTME, RTME, and TaTME, respectively. None achieved the expected success rate (85%), and propensity score analyses found no differences. Operative results were similar between high- and low-volume inclusion centers only for RTME. Conclusions: The RESET trial yielded high-quality results despite focusing on HRPs. Minimally invasive procedures showed similar sphincter-sparing procedure outcomes, but LTME included patients with more favorable tumors. Oncologic and functional outcomes will be evaluated at 2 years (ClinicalTrials.gov, ID: NCT03574493).